Lung cancer immunotherapy: progress, pitfalls, and promises
Aritraa Lahiri,Avik Maji,Pravin D. Potdar,Navneet Singh,Purvish M. Parikh,Bharti Bisht,Anubha Taneja Mukherjee,Manash K. Paul +7 more
Reads0
Chats0
TLDR
In this article , a detailed overview of the recent developments in the immunotherapeutic landscape in targeting small cell lung cancer (SCLC) and NSCLC (NSCLC), and the implication of nanomedicine in lung cancer immunotherapy as well as the combinatorial application of traditional therapy along with immunotherapy regimens are discussed.Abstract:
Abstract Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading to relapse. Immunotherapy is profoundly altering the approach to cancer treatment owing to its tolerable safety profile, sustained therapeutic response due to immunological memory generation, and effectiveness across a broad patient population. Different tumor-specific vaccination strategies are gaining ground in the treatment of lung cancer. Recent advances in adoptive cell therapy (CAR T, TCR, TIL), the associated clinical trials on lung cancer, and associated hurdles are discussed in this review. Recent trials on lung cancer patients (without a targetable oncogenic driver alteration) reveal significant and sustained responses when treated with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade immunotherapies. Accumulating evidence indicates that a loss of effective anti-tumor immunity is associated with lung tumor evolution. Therapeutic cancer vaccines combined with immune checkpoint inhibitors (ICI) can achieve better therapeutic effects. To this end, the present article encompasses a detailed overview of the recent developments in the immunotherapeutic landscape in targeting small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Additionally, the review also explores the implication of nanomedicine in lung cancer immunotherapy as well as the combinatorial application of traditional therapy along with immunotherapy regimens. Finally, ongoing clinical trials, significant obstacles, and the future outlook of this treatment strategy are also highlighted to boost further research in the field. read more
Citations
More filters
Journal ArticleDOI
Screening biomarkers for predicting the efficacy of immunotherapy in patients with PD-L1 overexpression.
Journal ArticleDOI
Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small‑cell lung cancer: a retrospective comparative cohort study
Yuxia Zou,Xueru Ren,Huanhuan Zhang,Yuenan Wang,Hanjin Wang,Rubing Bai,Zhihong Zhang,Gengyun Sun +7 more
TL;DR: In this article , the authors evaluated the efficacy and safety of atezolizumab plus chemotherapy and durvalumab+ chemotherapy in the treatment of SCLC in a real-world setting.
Journal ArticleDOI
Enhanced recovery of postoperative nursing for single-port thoracoscopic surgery in lung cancer patients
Xiufen Hu,Xiaodan He +1 more
TL;DR: In this paper , the authors reviewed the research progress on rapid rehabilitation nursing in single-port thoracoscopic lung cancer surgery and showed that rapid rehabilitation surgery can actively improve the prognosis of patients with different types of cancer and promote early recovery.
Journal ArticleDOI
The role of immunotherapy in lung cancer: Actual scenery
TL;DR: In this paper , the authors present some emerging goals and attemps in cancer immunotherapy, including immune checkpoint blockade, adaptive cellular therapies connected on the infusion of tumor-struggling immune cells into the body.
Journal ArticleDOI
Advances in liposome research in the field of antitumor
TL;DR: In this article , the mechanisms of action of different types of targeted liposomes and their specific role in overcoming tumor resistance, immunotherapy and helping drugs to cross the blood-brain barrier are discussed.
References
More filters
Journal ArticleDOI
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
Journal ArticleDOI
Cancer statistics, 2018
TL;DR: The combined cancer death rate dropped continuously from 1991 to 2015 by a total of 26%, translating to approximately 2,378,600 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Journal ArticleDOI
Cancer statistics, 2017
TL;DR: The American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.
Journal ArticleDOI
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Journal ArticleDOI
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Related Papers (5)
Cancer Immunoediting in the Development of Cancer Immunotherapy
Ryo Ariyasu,Hiroyoshi Nishikawa +1 more